Annexon, Inc. Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing is an annual report rather than a standalone fourth-quarter report. Annexon is a clinical-stage biopharmaceutical company developing complement-pathway medicines targeting C1q or related classical-pathway components. It has no approved products and generated no product revenue.
Business Context and Pipeline
- ANX005: Intravenous anti-C1q antibody in a pivotal Phase 3 trial for Guillain-Barré syndrome (GBS); 241 patients enrolled. Data were expected in the second quarter of 2024. FDA Fast Track and orphan designations and EMA orphan designation have been granted.
- ANX007: Intravitreal anti-C1q Fab for geographic atrophy (GA). In the Phase 2 ARCHER trial, monthly treatment significantly reduced the risk of at least 15-letter BCVA loss, but the primary lesion-growth endpoint was not statistically significant. Phase 3 ARCHER II was planned for mid-2024 and Phase 3 ARROW, a head-to-head study against SYFOVRE, for late 2024. EMA PRIME designation has been granted.
- ANX1502: Oral classical-complement inhibitor. A Phase 1 healthy-volunteer study showed generally good tolerability, no serious adverse events and supportive pharmacodynamic results. A CAD proof-of-concept study was planned for the first half of 2024, with data expected in the second half of 2024.
- Additional programs include ANX005 in Huntington’s disease and ALS and ANX009 in lupus nephritis; future development options were under evaluation.
Financial Highlights
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Product revenue | $0 | $0 | No change |
| Research and development expense | $113.8 million | $112.5 million | Up 1% |
| General and administrative expense | $30.0 million | $33.1 million | Down 9% |
| Total operating expenses | $143.7 million | $145.6 million | Down 1% |
| Interest and other income, net | $9.5 million | $3.7 million | Up 160% |
| Net loss | $134.2 million | $141.9 million | Loss decreased 5% |
| Basic and diluted net loss per share | $1.77 | $2.60 | Improved |
| Net cash used in operating activities | $121.1 million | $116.3 million | Use increased |
Gross operating margin and product margins are not meaningful because the Company has no commercial revenue. Stock-based compensation was $18.2 million in 2023, compared with $18.5 million in 2022.
Cash, Liquidity, Debt and Capitalization
- Cash and cash equivalents were $225.1 million at December 31, 2023; short-term investments were $34.6 million, for total cash resources of approximately $259.7 million. Including restricted cash, cash, cash equivalents and restricted cash totaled $226.1 million.
- Management expected existing cash and short-term investments to fund planned operating expenses and capital expenditures into mid-2026, based on current plans. The filing states that additional financing will be required to achieve longer-term objectives and to complete the planned ARROW trial.
- The Company reported total liabilities of $47.1 million, consisting primarily of operating lease liabilities. The filing does not identify conventional funded debt.
- Net cash provided by financing activities was $135.5 million. December 2023 financing generated approximately $117.0 million of net proceeds from common stock and pre-funded warrants. The Company also raised approximately $17.5 million through its 2021 ATM program during 2023.
- As of December 31, 2023, 78.4 million common shares were outstanding, with pre-funded warrants for approximately 40.5 million shares and common warrants for approximately 8.4 million shares outstanding. These instruments create substantial potential dilution.
- Subsequent to year-end, the Company raised approximately $32.3 million through the 2021 ATM program through the filing date and established a new $100 million ATM program in March 2024, with no sales under that program as of the filing date.
Material Changes Versus 2022
- Net loss declined by $7.7 million, primarily because higher interest income and lower general and administrative expense more than offset modestly higher research and development expense.
- Research and development spending shifted toward contract manufacturing and personnel. Contract manufacturing increased $7.5 million, while clinical and nonclinical outside services decreased $11.9 million, largely reflecting completion of the Phase 2 ARCHER trial.
- Cash resources increased materially following the December 2023 financing and ATM activity, although operating cash burn increased to $121.1 million from $116.3 million.
- Common shares outstanding increased from 47.7 million to 78.4 million, excluding the substantial additional shares issuable under warrants.
- The Company prioritized ANX005 for GBS, ANX007 for GA and ANX1502 for autoimmune indications, while reducing emphasis on certain other programs.
Outlook, Risks and Unusual Items
- Near-term value depends heavily on Phase 3 GBS results, regulatory acceptance of foreign clinical data and the IGOS real-world evidence comparability analysis, expected in the first half of 2025 to support a potential ANX005 BLA.
- ANX007 faces execution, financing and regulatory risks. The Phase 2 trial produced positive visual-function results but missed its primary lesion-growth endpoint. FDA acceptance of the planned global sham-controlled ARCHER II trial, the ARROW comparator design and the eventual data package is not assured.
- The Company relies on third-party contract manufacturers, clinical research organizations and suppliers. Manufacturing capacity, quality, supply interruptions or regulatory findings could delay development or approval.
- All product candidates remain investigational. Clinical trials may fail, be delayed, require additional studies or reveal adverse effects, and regulatory designations do not assure approval.
- Competition includes approved GA therapies SYFOVRE and avacincaptad pegol, approved CAD therapy sutimlimab and numerous clinical-stage complement-targeted programs.
- Clinical development and commercialization will require substantial additional capital. Future equity financing could dilute shareholders; debt financing could impose covenants and repayment obligations.
- The Company had no material legal proceedings and reported effective disclosure controls and internal control over financial reporting. As a smaller reporting company, it was not required to provide an auditor attestation of internal control effectiveness.
- The filing discloses a 2024 cyberattack at a vendor that briefly interrupted access to a third-party system; the Company stated that it was monitoring the incident and had implemented mitigating procedures.
- Patent protection varies by product and jurisdiction. Certain licensed U.S. patents expire between 2026 and 2030, while other owned patents extend into the 2030s and 2040s, absent extensions or other changes.
Investor Verification Checklist
- Verify the Phase 3 ANX005 GBS efficacy and safety results and whether the FDA accepts the foreign-trial and IGOS comparability evidence for a BLA.
- Verify final and regulatory-relevant interpretation of ANX007 ARCHER data, including the missed lesion-growth endpoint, and enrollment, design and funding of ARCHER II and ARROW.
- Track ANX1502 CAD proof-of-concept results and whether the tablet formulation supports further autoimmune development.
- Reconcile cash burn with the stated mid-2026 runway, particularly after expansion of the GA program and additional ATM sales.
- Assess dilution from approximately 40.5 million pre-funded warrant shares, 8.4 million common warrant shares, equity awards and future ATM offerings.
- Review clinical supply, contract manufacturing readiness and any regulatory inspection issues affecting planned BLA or marketing applications.
- Monitor competitive and reimbursement developments in GA, GBS and CAD, including the performance and safety of approved or competing therapies.
- Review patent expiry, license obligations and the potential impact of third-party intellectual-property challenges.